jeffrey sharman, md, on the benefits of zanubrutinib as compared to other btk inhibitors
Published 4 years ago • 67 plays • Length 0:48
Download video MP4
Download video MP3
Similar videos
-
1:34
mazyar shadman, md, on the efficacy & tolerability of zanubrutinib in b-cell malignancies
-
1:42
jeff sharman, md, on the outcomes of captivate study investigating ibrutinib and venetoclax
-
0:47
lori leslie, md, considers the use of zanubrutinib in relapsed/refractory mantle cell lymphoma
-
1:05
chaitra ujjani, md, considers the ideal patient profile for zanubrutinib in rr-mcl
-
2:04
dr. treon on the evolution of btk inhibitors in waldenström macroglobulinemia
-
1:34
jeff sharman, md, shares results of the genuine phase 2 study presented at asco 2017
-
3:58
prof. jeff sharman: results of the phase iii genuine study
-
4:50
ngs across tumor types for trk inhibition
-
2:50
dr. anthony d'ambrosio md, mba, faans
-
1:08
ryan lynch, md, considers the ideal patient profile for zanubrutinib in rr-mcl
-
26:12
fen ben for cancer?
-
21:21
inflammasome activation in acute covid-19 - judy lieberman, md, phd
-
1:06
ph.d. student jeff on the resources and facilities in the lab
-
0:37
jeffrey hymes, md, on getting vaccinated for protection and immunity
-
15:18
brain tumor genomics/epigenomics - david a. solomon, md, phd
-
3:24
wvu medicine | jonathan sherman, md, faans, facs | part one
-
2:33
novel btk inhibitors for waldenström’s macroglobulinemia
-
7:14
2017 nam annual meeting: concluding remarks by the program chair
-
1:35
jess g snedeker, metabolic diseases and tendinopathies: the missing link
Clip.africa.com - Privacy-policy